logo-loader

Oncimmune's study data to be featured at prestigious cancer research conference

Published: 08:13 14 May 2020 BST

Oncimmune -

Oncimmune Holdings PLC (LON:ONC) has said findings from one of its studies are to be featured at a prestigious international cancer research conference this month.

The immunodiagnostics group announced that its data from profiling tumour associated antibodies in melanoma patients receiving immune checkpoint inhibitors has been selected as a featured presentation at the upcoming American Society of Clinical Oncology 2020 – ASCO for short – Virtual Scientific Programme, which will take place from May 29 to May 31.

The featured presentation will review data assessing samples from patients receiving either Pembrolizumab, Ipilimumab, Nivolumab monotherapy, or combination therapy of Ipilimumab and Nivolumab, which have been analysed on Oncimmune's proprietary biomarker discovery engine, SeroTag.

The data identified that autoantibodies have a role in predicting clinical outcomes or immune-related adverse events (irAEs).

The presentation will be the first time that the clinical utility of autoantibodies has been presented at this prestigious international cancer research conference.

“This study provides further evidence that autoantibodies play an important role in identifying patients likely to suffer irAEs in response to cancer immunotherapy, this time in patients suffering from melanoma. Importantly, the study also reinforces the evidence base underpinning the utility of tumour-related antibodies in predicting clinical responses to commonly used first-line treatment immunotherapies,” Adam Hill, the chief executive officer of Oncimmune said in a statement.

"Oncimmune is at the forefront in understanding the utility of autoantibodies in a clinical setting. This exciting study demonstrates the strides we have made in unlocking the potential of our autoantibody platform to improve patient outcomes," he added.

Oncimmune's strategic pivot aims for robust growth in 2024

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone joins Proactive's Stephen Gunnion with highlights of the company's 2023 performance, which included its strategic decision to focus on its ImmunoINSIGHTS platform. A significant development was the sale of its early lung cancer detection...

3 weeks, 1 day ago